[eDisclosure Notice] LG Chem Applies for European Phase 3 Clinical Trial Plan for Gout Treatment, etc. (Morning Summary)

[Asia Economy Reporter Minji Lee] LG Chem announced on the 16th that it has applied to Spain's AEMPS for a Phase 3 clinical trial plan to evaluate the efficacy and safety of Tigulixostat in lowering blood uric acid levels in patients with hyperuricemia gout.

The company stated, "We plan to submit clinical trial plans to other countries and proceed with clinical trials," adding, "As an oral gout treatment with rapid onset of action and once-daily dosing, it is expected to improve patient compliance and convenience."

▲Hankom Lifecare=Signed a supply contract worth 20.8 billion KRW for 19 items including new small unit combat training equipment systems.

▲Able C&C=Korea Exchange requested a disclosure inquiry regarding reports of a sale of the largest shareholder's stake in Able C&C.

▲HSD Engine=HSD Engine signed a ship engine supply contract worth 119.6 billion KRW with Daewoo Shipbuilding & Marine Engineering.

▲Sangji Kailum=Won a military base facility construction contract worth 2.8 billion KRW.

▲Shinwon General Development=Announced signing a construction contract worth 9 billion KRW with Wonik QnC.

▲Codem=Announced convening an extraordinary general meeting on the 30th to decide on amendments to the articles of incorporation, capital reduction, and director appointments.